Adero Partners LLC Acquires 156 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Adero Partners LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,642 shares of the biopharmaceutical company’s stock after buying an additional 156 shares during the period. Adero Partners LLC’s holdings in Gilead Sciences were worth $296,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Norges Bank bought a new position in shares of Gilead Sciences in the fourth quarter worth $1,789,254,000. FMR LLC boosted its stake in Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock worth $3,724,306,000 after purchasing an additional 7,157,113 shares during the period. GAMMA Investing LLC grew its holdings in Gilead Sciences by 13,891.1% during the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock valued at $285,761,000 after buying an additional 2,532,070 shares in the last quarter. Northern Trust Corp increased its position in shares of Gilead Sciences by 19.7% during the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock valued at $1,377,707,000 after buying an additional 2,458,954 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter worth about $207,340,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

GILD stock opened at $110.83 on Tuesday. The firm has a market cap of $137.86 billion, a P/E ratio of 299.54, a P/E/G ratio of 0.71 and a beta of 0.29. The firm’s fifty day moving average is $105.82 and its 200 day moving average is $102.45. Gilead Sciences, Inc. has a 52 week low of $62.69 and a 52 week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion for the quarter, compared to analysts’ expectations of $6.77 billion. During the same period last year, the firm earned ($1.32) earnings per share. The company’s revenue for the quarter was down .3% compared to the same quarter last year. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.85%. Gilead Sciences’s dividend payout ratio (DPR) is currently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the transaction, the chief financial officer now directly owns 165,674 shares of the company’s stock, valued at approximately $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the sale, the chief executive officer now directly owns 620,268 shares in the company, valued at $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,000 shares of company stock worth $4,630,310. 0.27% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GILD. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. Oppenheimer reduced their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, April 25th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Wells Fargo & Company lifted their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.